Reisa A. Sperling
Co-Investigator, Neuroimaging Core, Massachusetts Alzheimer’s Disease Research Center, Director, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Professor of Neurology, Harvard Medical School, Remondi Family Distinguished Chair in Neurology
Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School
(617) 525-8675
Dr. Sperling’s research is focused on the early diagnosis and treatment of Alzheimer’s disease. Her recent work involves the use of functional MRI and PET amyloid imaging to study alterations in brain function during in aging and early Alzheimer’s disease. She is the Principal Investigator on multiple NIH and Foundation grants to study the neural basis of memory impairment in MCI and AD, and the relationship of amyloid deposition to memory function.
Dr. Sperling has received the American Academy of the Neurology Clinical Research Fellowship Award, the Harvard Medical School Scholars in Medicine Fellowship, the Alzheimer’s Association Memory Ride Award, a Paul Beeson Faculty Scholars in Aging Award, and the 2007 American Academy of Neurology Research in Geriatric Neurology Award.
More Information: Sperling Profile
Dr. Reisa Sperling is a neurologist, specializing in dementia and imaging research. She is a Professor in Neurology at Harvard Medical School. She is also the Director of the Center for Alzheimer Research and Treatment at Brigham and Womenís Hospital, and the Director of the Neuroimaging Core and the Outreach Core of the Massachusetts Alzheimerís Disease Research Center at Massachusetts General Hospital.
Dr. Sperling’s research is focused on the early diagnosis and treatment of Alzheimer’s disease. Her recent work involves the use of functional MRI and PET amyloid imaging to study alterations in brain function in aging and early Alzheimer’s disease. She is the Principal Investigator on multiple NIH and Foundation grants utilizing multi-modality imaging techniques to probe the neural correlates of memory changes in cognitive aging and early AD. She is the PI of the Harvard Aging Brain Study, funded by a NIA Program Project grant. Dr. Sperling oversees a number of clinical trials of potential disease-modifying therapeutics in early Alzheimerís disease, and serves on the Steering Committees for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer Network. She has published over 120 peer-reviewed research articles on memory, aging, and early AD.
Dr. Sperling led the National Institute on Aging-Alzheimer’s Association working group to develop guidelines for the study of Preclinical Alzheimer’s disease. She serves as the Project Leader for the ADCS Anti-Amyloid Treatment in Asymptomatic AD (A4 trial), a 3 year secondary prevention trial in 1000 clinically normal older individuals with biomarker evidence of early AD pathology.
Miller SL, Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, Pihlajam ki M, Sperling RA. Age-Related Memory Impairment associated with Loss of Parietal Deactivation but Preserved Hippocampal Activation. Proc Natl Acad Sci USA 2008; 105: 2181-2196. [PMCID: 2538895].
Buckner R, Sepulcre J, Talukdar T, Krienen F, Liu H, Hedden T, Andrews-Hanna J, Sperling R, Johnson K. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer’s Disease. J Neurosci 2009; 29: 1860-1873. [PMCID: 2750039].
Chua EF, Schacter DL, Sperling RA. Neural Basis for Recognition Confidence in Younger and Older Adults. Psychology and Aging 2009; 24: 139-153. [PMCID: 2657923].
Salloway SP, Sperling RA, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck C, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A Phase 2 Multiple Ascending Dose Trial of Bapineuzumab in Mild to Moderate Alzheimer’s Disease. Neurology 2009; 73: 2052-2053. [PMCID: 2790221].
Sperling RA, LaViolette PS, O’Keefe K, O’Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DS, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid Deposition is associated with Impaired Default Network Function in Older Persons without Dementia. Neuron 2009; 63: 178-188. [PMCID: 2738994].
Pihlajam‰ki M, O’Keefe K, Bertram L, Tanzi R, Dickerson B, Blacker D, Albert M, Sperling RA. Evidence of Altered Posteromedial Cortical fMRI Activity in Subjects at Risk for Alzheimer Disease. Alzheimer Dis Assoc Diord 2010; 24: 28-36. [PMCID: 2837131].
More publications may be found at www.ncbi.nlm.nih.gov/